ABPI statement on MHRA report

The Association of the British Pharmaceutical Industry has issued a statement in response to the government's announcement of new legislation for the regulation of clinical trials. The news follows from a statement from the Medicines and Healthcare products Regulatory Agency (MHRA).

Patient safety is of paramount importance to the pharmaceutical industry, the ABPI said, adding that the "industry is already required by legislation to undertake ongoing monitoring of its medicines both during development and after launch."

The ABPI stated that it has not yet examined details of the proposed legislation and "looks forward" to the consultation process. However, the group said it welcomes efforts to provide "further genuine protection for the patient, without simply adding unnecessary bureaucracy."